Pathophysiology: Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for several difficult-to-treat infections in humans. It is also called oxacillin-resistant Staphylococcus aureus. MRSA is especially troublesome in hospitals, prisons, and nursing homes, where patients with open wounds, invasive devices, and weakened immune systems are at greater risk of nosocomial infection than the general public.S. aureus most commonly colonizes under the anterior nares.
Statistics: The number of death certificates mentioning Meticillin-resistant Staphylococcus aureus fell by 20% from 364 in 2011 to 292 in 2012. Of the 292 death certificates mentioning MSRA, 38 (13%) also identified this organism as the underlying cause of death. Prevalence rates decreased by 79% in males and 76% in females between 2008 and 2012. In the period 2008–12, MRSA death rates increased with age and were higher for males than for females.
Treatment: Treatment for MRSA will depends up on the how prevalence it is and also on the type of the infection caused. Mostly Treatment options for MRSA skin and soft tissue infections may include ClindamycinTetracycline drugs, Doxycycline and Minocycline,Trimethoprim and Sulfamethoxazole, Rifampin and Linezolid.
Major Research: An entirely different approach is phage therapy (e.g., at the Eliava Institute in Georgia). Experimental phage therapy tested in mice had a reported efficacy against up to 95% of tested Staphylococcus isolates.It has been reported that maggot therapy to clean out necrotic tissue of MRSA infection has been successful. Studies in diabetic patients reported significantly shorter treatment times than those achieved with standard treatments.